TOP TEN perturbations for 1553079_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553079_at
Selected probe(set): 1553079_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553079_at (1553079_at) across 6672 perturbations tested by GENEVESTIGATOR:

ulcerative colitis study 11 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):3.661687
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

ulcerative colitis study 11 / colorectal cancer study 13 (crc)

Relative Expression (log2-ratio):3.4775543
Number of Samples:3 / 7
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (crc)
Colon biopsies derived from patients with colorectal carcinoma.

ulcerative colitis study 11 / normal colon tissue

Relative Expression (log2-ratio):3.1334934
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control normal colon tissue
Colon biopsies derived from healthy controls.

ulcerative colitis study 11 / colorectal cancer study 13 (hypp. pol.)

Relative Expression (log2-ratio):3.0544033
Number of Samples:3 / 11
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (hypp. pol.)
Colon biopsies derived from patients with hyperplastic polyps.

ulcerative colitis study 55 (left-sided colitis) / ulcerative colitis study 55 (dysplasia)

Relative Expression (log2-ratio):2.5390472
Number of Samples:20 / 6
Experimental ulcerative colitis study 55 (left-sided colitis)
Descending colonic mucosal biopsies obtained from patients with left-sided ulcerative colitis (UC). Patients characteristics: Age (median IQR): 42 (30); Years with disease (<10 yr/>10 yr): 13/7; Mayo score (median IQR): 6 (4); Mayo endoscopic score (median IQR): 2 (0); Smoking/nonsmoking: 3/17. 18 patients received daily medication.
Control ulcerative colitis study 55 (dysplasia)
Descending colonic mucosal biopsies from dysplasia obtained from patients with ulcerative colitis (UC). Patients characteristics: Age (median IQR): 49 (28); Years with disease (<10 yr/>10 yr): 2/4; Mayo score (median IQR): 1.5 (5); Mayo endoscopic score (median IQR): 0.5 (2); Low-grade/high-grade dysplasia: 5/1; 4 patients received daily medication.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):1.8836956
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 3 (baseline; responder; colon) / normal colon mucosa tissue

Relative Expression (log2-ratio):1.8708858
Number of Samples:12 / 6
Experimental Crohn's disease study 3 (baseline; responder; colon)
Colonic mucosal biopsies derived from Crohn's disease patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 10 / colorectal cancer study 13 (crc)

Relative Expression (log2-ratio):1.8559151
Number of Samples:4 / 7
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (crc)
Colon biopsies derived from patients with colorectal carcinoma.

ulcerative colitis study 31 (active) / ulcerative colitis study 31 (quiescent)

Relative Expression (log2-ratio):1.8470659
Number of Samples:14 / 8
Experimental ulcerative colitis study 31 (active)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients with active disease. Clinical and histological disease was assessed using the total Mayo score and the Matts score. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.
Control ulcerative colitis study 31 (quiescent)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients in remission. Clinical and histological disease was assessed using the total Mayo score and the Matts score. Patients had been in remission for at least 5 months before and after biopsy collection. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.

ulcerative colitis study 5 (baseline; responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):1.8356161
Number of Samples:8 / 6
Experimental ulcerative colitis study 5 (baseline; responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.